Effectiveness of EGFR‐TKI rechallenge immediately after PD ‐1 blockade failure-Reference-Cited by-同舟云学术

Effectiveness of EGFR‐TKI rechallenge immediately after PD ‐1 blockade failure

Published:2021-01-31 Issue:6 Volume:12 Page:864-873
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Kaira Kyoichi¹^ORCID,Kobayashi Kunihiko¹,Shiono Ayako¹,Yamaguchi Ou¹^ORCID,Hashimoto Kosuke¹,Mouri Atsuto¹,Shinomiya Shun¹,Miura Yu¹,Imai Hisao¹,Kagamu Hiroshi¹

Affiliation:

1. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13864

Reference16 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

4. High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy

5. Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI–Resistant Patients

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Potential of Artificial Intelligence for Predicting PD-L1 Expression and EGFR Mutations in Lung Cancer: A Systematic Review and Meta-Analysis;Journal of Computer Assisted Tomography;2024-08-12

2. Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC;Oncology and Therapy;2024-07-30

3. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

4. PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy;Cell Death & Differentiation;2024-05-30

5. Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis;ImmunoTargets and Therapy;2024-05